Payment overview · 2025
General Payments
$215.00
3 reported records · 3 companies
Healthcare provider profile · identity verified
Kyu D Ahn, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · POMONA, CA · NPI 1427015593
Verified facts
What the public records show
CMS Open Payments records show Kyu D Ahn, M.D. received $215.00 in general payments during 2025 across 3 reported records.
Penumbra, Inc. accounted for 79.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Zenpep by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $170.43 | 79.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.16 | 11.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.41 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $170.43 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1065 | 271 |
| Amlodipine Besylate | Amlodipine Besylate | 759 | 176 |
| Vascepa | Icosapent Ethyl | 623 | 138 |
| Losartan Potassium | Losartan Potassium | 532 | 126 |
| Metformin Hcl Er | Metformin Hcl | 361 | 90 |
| Metformin Hcl | Metformin Hcl | 296 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 78 |
| Famotidine | Famotidine | 242 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 68 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 230 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 59 |
| Benazepril Hcl | Benazepril Hcl | 190 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 176 | 43 |
| Icosapent Ethyl | Icosapent Ethyl | 176 | 49 |
| Simvastatin | Simvastatin | 170 | 41 |
| Gabapentin | Gabapentin | 163 | 36 |
| Lisinopril | Lisinopril | 151 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 41 |
| Raloxifene Hcl | Raloxifene Hcl | 147 | 34 |
| Alendronate Sodium | Alendronate Sodium | 137 | 35 |
| Eliquis | Apixaban | 133 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 44 |
| Finasteride | Finasteride | 126 | 32 |
| Furosemide | Furosemide | 125 | 33 |
| Trazodone Hcl | Trazodone Hcl | 122 | 33 |
| Carvedilol | Carvedilol | 114 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 28 |
| Jardiance | Empagliflozin | 111 | 26 |
| Glipizide Er | Glipizide | 104 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 30 |
| Atenolol | Atenolol | 99 | 25 |
| Azithromycin | Azithromycin | 97 | 79 |
| Lovastatin | Lovastatin | 92 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 25 |
| Sertraline Hcl | Sertraline Hcl | 90 | 18 |
| Omeprazole | Omeprazole | 85 | 27 |
| Potassium Chloride | Potassium Chloride | 85 | 20 |
| Donepezil Hcl | Donepezil Hcl | 83 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 43 |
| Clonidine Hcl | Clonidine Hcl | 68 | 22 |
| Glipizide | Glipizide | 68 | 16 |
| Ibuprofen | Ibuprofen | 68 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 20 |
| Chlorthalidone | Chlorthalidone | 57 | 17 |
| Valsartan | Valsartan | 56 | suppressed |
| Glimepiride | Glimepiride | 55 | 11 |
| Prednisone | Prednisone | 54 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Allopurinol | Allopurinol | 50 | 17 |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 13 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Baclofen | Baclofen | 39 | 16 |
| Lorazepam | Lorazepam | 38 | 16 |
| Meloxicam | Meloxicam | 38 | 14 |
| Linzess | Linaclotide | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | 11 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 15 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Levofloxacin | Levofloxacin | 28 | 18 |
| Nateglinide | Nateglinide | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Minoxidil | Minoxidil | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 24 |
| Ozempic | Semaglutide | 24 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | 16 |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.00 · 3 records | Penumbra, Inc. | ELIQUIS, NURTEC ODT, RUBY Coil, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error